Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of CVT-301 (levodopa inhalation powder) in Parkinson's disease "off" episodes
2012-000181-37Phase 2Completed
- Sponsor
- Civitas Therapeutics
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Parkinson's disease (PD) comparing CVT-301 inhaled levodopa with Placebo inhalation (2 arms). Primary endpoints: Pharmacokinetics of inhaled levodopa (CVT-301), Safety and tolerability of CVT-301 and 1 more. Started Feb 2012; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2012-000181-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000181-37.